New use of PDGFRbeta inhibitors for treatment of T-cell lymphomas

The major clinical challenge in treating NPM-ALK+ anaplastic large cell
lymphomas (ALCL) is its high rate of relapse. Researchers of the Medical
University of Vienna identified high expression of PDGFRß in the NPMALK
induced ALCL. Pharmaceutical targeting of PDGFRB using a tyrosine
kinase inhibitor (TKI) strongly reduced tumor size in SCID-mice xenografted with NPM-ALK mouse tumor cells, and increased the survival of NPM-ALK+ transgenic mice by more than 90%. These data provide evidence for the use of FDA approved tyrosine kinase inhibitors for the effective treatment of lymphomas and encourage the development of specific clinical trials.

Further information: PDF

Wissenstransferzentrum Ost (WTZ Ost)
Phone: +43 1 401 60 25 202

Contact
Dr. Michael Hoschitz

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.